Cemiplimab (Libtayo): Uses and Availability in India

Cemiplimab is a monoclonal antibody that blocks PD-1, a switch on the surface of T cells. Tumours use that switch to shut the T cell down. Blocking it aims to let the immune system recognise and attack the cancer. Libtayo is the brand name. Cemiplimab is the molecule inside it.

It is a fully human antibody developed by Regeneron Pharmaceuticals, originally in collaboration with Sanofi. The US Food and Drug Administration approved it in September 2018. The European Medicines Agency authorised it in June 2019, initially as a conditional authorisation, converted to a standard authorisation on 1 July 2022.

Two things follow from the mechanism. First, cemiplimab does not attack cancer cells directly the way chemotherapy does. It works only where the person still has T cells able to respond, which is why it helps in a proportion of patients rather than in everyone who receives it. Second, taking a brake off the immune system can let that system turn on healthy organs. That is where immune-related adverse events come from, and they are covered further down this page.

It is not an immunity booster, not a general tonic, and not something that can be added to another treatment plan without the treating team knowing.

Mechanism and authorisation dates here follow the European Medicines Agency public medicine overview for Libtayo and the US FDA approval record.

Cemiplimab is approved for a short, specific list. Advanced skin cancer is its core use: cutaneous squamous cell carcinoma and basal cell carcinoma. It is also approved for non-small-cell lung cancer in defined first-line settings, and in the European Union for recurrent or metastatic cervical cancer. It is not a general cancer treatment.

This is the part most search results get wrong. Almost every article about PD-1 medicines is written around lung cancer, because that is where the volume is. Cemiplimab is the exception in the class. In September 2018 it became the first medicine approved anywhere specifically for advanced cutaneous squamous cell carcinoma — a cancer that, until then, had no approved systemic option once surgery and radiation had been exhausted. That is the reason this molecule exists, and skin remains the setting where guideline bodies place it first. If a prescription in your hand names cemiplimab, skin cancer is the more likely reason, not lung.

How often does the tumour actually shrink?

The European Medicines Agency publishes the response figures behind these authorisations. In the main skin-cancer study of 193 adults, the cancer shrank in around 39% of people with metastatic cutaneous squamous cell carcinoma and in around 44% of those with locally advanced disease. In basal cell carcinoma, the cancer shrank in around 32% of people with locally advanced disease and around 29% of those with metastatic disease.

Read those numbers honestly. They are response rates in selected trial populations, reported by a regulator, and they describe tumour shrinkage rather than any promise about an individual. They also mean that in each of those groups, most people treated did not have their tumour shrink. No page can tell you which group you would be in. Your own oncologist, working from your reports, is the only person who can weigh that.

On publicly available information as of August 2026, Libtayo is not marketed commercially in India. There is no Indian brand, no Indian maximum retail price and no biosimilar. Patients prescribed it here usually obtain it through a named-patient import arrangement organised by the treating hospital with a licensed importer.

On the regulatory position: a current CDSCO marketing approval for cemiplimab could not be confirmed on the regulator's public approval lists at the time of writing. That status should be treated as unconfirmed rather than asserted either way. It can change, and the hospital pharmacy or the treating oncologist is the right place to confirm it for a specific case.

A named-patient import is a legal route for bringing in a medicine that is not marketed in India, for one named individual, on a prescription, with the required permissions and paperwork. It is not a workaround and it is not something a family should attempt through an unverified online seller. What it means in practice:

• Time. Weeks, not days, between the prescription and the first vial. That matters when a treatment plan has a start date.
• Cold chain. The vial must stay between 2 and 8°C for the whole journey, through specialised temperature-controlled shipping. A break in that chain is not visible in the vial.
• Documentation. Prescription, import permission, invoices and batch records. Keep every page of it.
• No local support structure. No Indian patient-assistance programme, no local brand helpline, and a harder path for any insurance claim.
• Authenticity risk. Counterfeit checkpoint inhibitors have been reported entering the Indian market. Insist that any vial is dispensed through a licensed hospital pharmacy with documented handling, and refuse a loose vial offered outside that chain.

If the medicine cannot be obtained, that is a clinical conversation, not a dead end. Several other checkpoint inhibitors are approved and marketed in India, and whether one of them fits the diagnosis is a decision for the treating oncologist against the approved label. It is not a substitution a family or a supplier should make.

Cemiplimab is given as a drip into a vein, in a day-care unit. The standard dose is a fixed 350 mg every three weeks, infused over about 30 minutes, from a single-dose 350 mg vial. There is no tablet, and no version that can be taken at home.

The dose is flat, set by the schedule rather than calculated from body weight. A 50 kg patient and a 90 kg patient receive the same 350 mg. That is unusual among cancer medicines and it has a direct effect on cost, because a smaller patient does not pay less per cycle.

1. Before the cycle — blood tests check thyroid, liver, kidney and blood-count values, and you are asked about any new symptom since the last cycle. Results can delay a cycle. That is routine caution, not a setback.
2. Review — the oncologist confirms the dose and that it is safe to proceed that day.
3. The infusion — a cannula is placed and the medicine runs in over about half an hour. No sedation is needed, and hair loss is not expected from this medicine itself.
4. Short observation — a period of monitoring for infusion reactions, longer after the first dose.
5. Between cycles — you watch for new symptoms and report them promptly. Immune side effects can appear weeks or months after a dose, and even after treatment has stopped.

How long it continues depends on the setting, and the adjuvant setting is the unusual one. In advanced disease, treatment generally continues while it appears to be working and is tolerated, reviewed at each scan. In the adjuvant skin-cancer setting the United States label describes a defined course: 350 mg every three weeks for 12 weeks followed by 700 mg every six weeks, or 350 mg every three weeks throughout, for up to 48 weeks. A defined stopping point changes the whole financial and emotional shape of the treatment, and it is worth confirming which of the two situations applies to you.

Some checkpoint inhibitors now have a short under-the-skin injection version that takes minutes instead of a drip. Cemiplimab does not — it remains intravenous. The wider trade-off is set out in Subcutaneous Injection vs IV Drip Versions of Immunotherapy.

The commonest reported effects are fatigue, rash, itching, diarrhoea, nausea and muscle or joint pain. The characteristic risk is an immune-related adverse event, where the immune system attacks a healthy organ. Most are manageable when reported early. A few are medical emergencies.

Immune-related events are defined as much by when they appear as by what they are. That is why pre-cycle blood tests continue for the whole course, and why a symptom appearing weeks after a dose still counts.

Symptoms that need urgent assessment, not home management: new or worsening breathlessness or a persistent dry cough; loose motions that increase in number or contain blood; chest pain or palpitations; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin; a blistering or peeling rash, or sores in the mouth or eyes. For any of these, contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate and do not wait for the next scheduled cycle. Tell any doctor who sees you, in any department, that you are on immunotherapy — it changes how these symptoms are investigated.

The severe skin reactions deserve a line of their own on a medicine used mainly for skin cancer. The European Medicines Agency lists Stevens-Johnson syndrome and toxic epidermal necrolysis among the reactions reported with cemiplimab. A new rash that blisters, peels, or involves the mouth or eyes is not a minor skin complaint on this treatment.

Detailed, symptom-by-symptom guidance sits on the dedicated side-effect pages rather than here. This page is an orientation to the medicine, not a triage tool.

There is no Indian price for cemiplimab, because it is not marketed here. Published figures from other markets give the order of magnitude. Regeneron's launch announcement of September 2018 put the United States list price at USD 9,100 per three-week treatment cycle. A Canadian reimbursement review listed a submitted price of CAD 8,200 per 350 mg vial.

Both of those are published foreign figures, indicative as of August 2026. Neither is an Indian price and neither is a CION price. No rate is published here against this molecule. This page is editorial: it does not state or imply that this medicine is stocked, supplied or priced by CION Cancer Clinics.

Five things decide what an imported course actually costs an Indian family, and the headline vial figure is only the first.

• The dose is flat, not weight-based — 350 mg is 350 mg regardless of body weight, so the per-cycle drug cost does not fall for a smaller patient.
• The number of cycles — the real multiplier. An adjuvant course has a defined ceiling of up to 48 weeks. In advanced disease the course is open-ended and reviewed at each scan.
• The import layer — customs duty, temperature-controlled freight, importer charges and documentation, none of which exist for a locally marketed medicine.
• Everything around the infusion — day-care charges, pre-cycle blood tests and consultations.
• Response-assessment imaging — PET-CT between cycles is generally coordinated at partner imaging centres rather than performed inside the treating unit, and is billed separately.

No biosimilar route. There is no cemiplimab biosimilar anywhere as of August 2026, and the price relief that biosimilar competition brings elsewhere does not apply here. Nivolumab is the contrast: its Indian patent lapsed in May 2026 and a domestic biosimilar launched in January 2026 at roughly a quarter of the reference price (indicative, as of August 2026). Pembrolizumab's protection is expected to begin lapsing around 2028 to 2029. Cemiplimab sits outside both stories.

Insurance and schemes. Cover for an imported, non-marketed medicine is considerably harder to secure than for one approved and sold in India. Many policies exclude medicines that are not approved and marketed here. Ask the insurer or the scheme desk for the position in writing before the first cycle, and ask specifically whether an imported drug, the day-care charge and the imaging are each covered. Aarogyasri and other state-scheme packages have their own ceilings and their own inclusion lists, and any figure quoted anywhere, including here, is indicative as of August 2026 and changes.

If the practical problem is that cemiplimab is not sold in India, the useful next question is which PD-1 medicines are. Tislelizumab: What It Is and Whether It Is Available in India covers one of the newer entrants and the same availability question. Toripalimab, Sintilimab and Other Newer PD-1 Medicines sets out the wider group of newer molecules and where each one currently stands.

For the full picture across checkpoint inhibitors, biosimilars, verification and cost, start from Immunotherapy Medicines Explained. For how immunotherapy works as a treatment rather than as a list of molecules, the main immunotherapy section is the place to begin.